Sydney M Crago

The EURETINA meeting featured new treatments in gene therapy and innovative implants to enhance patient quality of life.

David R. Lally, MD, discusses promising results from the ARCHER trial on ANX007 for age-related macular degeneration, emphasizing the need for vision-preserving treatments.

Learn how the YOURS Committee empowers young retina specialists through engaging educational initiatives, networking opportunities, and exam preparation resources.

Dr. Kristina Pfau discusses her research on pseudoxanthoma elasticum and the initiatives of EURETINA's Young Ophthalmologist and Retina Specialists Committee.

Ultra-high-resolution OCT advances retinal imaging, enabling detailed visualization of disease progression and potential therapeutic effects in eye conditions.

Merck and EyeBio launch a pivotal trial for MK-3000, targeting diabetic macular edema with new treatment options to enhance patient outcomes.

Christine Kay, MD, presents new findings on MCO-010, a novel optogenetic therapy improving vision in retinitis pigmentosa patients at the Retina Society meeting.

Hear highlights from the Vit-Buckle Society and its presence at EURETINA 2025.

ISTH0036 demonstrates potential to prevent fibrosis, reduce retinal fluid, and improve vision in AMD and diabetic macular edema patients.

EURETINA's 25th anniversary meeting attracts 11,000 participants, showcasing cutting-edge research and fostering global networking among retina specialists.

Daniela Bacherini, MD, PhD, FEBO, said modern imaging modalities open up new possibilities in the peripheral retinal space.

Justis Ehlers discusses promising results from the HELIOS trial, revealing a novel treatment for diabetic retinopathy that may reduce treatment frequency.

The ultimate goal of redefining endpoints is enabling earlier diagnosis and treatment, said Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS

OCT-A angiography can help reveal early neurodegenerative disease signs, offering a noninvasive method for identifying high-risk patients through retinal analysis.

Neurotech Pharmaceuticals enhances its leadership by appointing Peter J. McDonnell, MD, a leading ophthalmology expert, to its Board of Directors.

identifeye HEALTH unveils a retinal screening platform, enhancing accessibility and efficiency in patient care through innovative technology and AI integration.

Research reveals a significant link between androgen exposure and central serous chorioretinopathy, aiding clinicians in assessing patient risk factors effectively.

Research reveals that GLP-1 medications, including semaglutide, do not increase diabetic retinopathy risks, offering reassurance for patients and prescribers.

Research reveals how neighborhood social factors impact patients with tractional retinal detachments, highlighting the need for improved access to care and support.

A look at podium presentations on GA research at ASRS 2025.